A Randomized, Double-Blind, Multi-Center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy

Trial Profile

A Randomized, Double-Blind, Multi-Center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GRANITE-1
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 16 Sep 2013 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top